Co-chief investigator REFRACT: Relapsed Follicular lymphoma Randomised trial Against standard ChemoTherapy: A randomised phase II trial of investigator choice standard salvage immunochemotherapy versus sequential novel therapy experimental arms CRUK/22/007

  • Kim Linton (Other)

Activity: Internal positions, career professional development, other peer review and other › Other › Research

Description

I conceived, designed and developed this ongoing trial with my co-CI, engaged new industry partnerships with Genmab/Abbvie and 4 academic researchers for embedded translational research, secured competitive Cancer Research UK (£1,414,249) & industry funding. REFRACT will accelerate approval of new treatments as the only randomised trial against standard chemo in relapsed/refractory FL (McIlvoy et al, 2024).
Period1 May 2022 → 31 Jul 2032
Degree of RecognitionInternational

Related content